Patrick Lefebvre
Education
M.A., economics and B.Sc., mathematics, Université Laval
Summary of Experience
Mr. Lefebvre specializes in the application of biostatistics and economics of health outcomes research. He has conducted and directed numerous studies in pharmacoeconomics, epidemiology, and health outcomes research in a variety of therapeutic areas such as anemia, asthma, cardiovascular diseases, chronic obstructive pulmonary disease, diabetes, genetic syndrome, hematology, hypertension, infectious diseases, myelodysplastic syndromes, neurological disorders, obesity, oncology, renal diseases, respiratory diseases, and women’s health. His recent work in the health care sector includes numerous clinical trials and medical claims data analyses to investigate resource utilization patterns, patient-reported quality of life, clinical effectiveness, direct medical and indirect productivity costs of a disease burden, and cost-effectiveness associated with the use of pharmaceuticals.
His extensive research is reflected in over 100 peer-reviewed publications in prominent clinical and health economics journals, such as Neurology, Journal of Allergy and Clinical Immunology, Journal of the American Society of Nephrology, Cancer, Hypertension, American Journal of Managed Care, Journal of Managed Care Pharmacy, Value in Health, and PharmacoEconomics. His scientific research has also resulted in numerous presentations at health care conferences as well as presentations to the FDA and CMS, and has included several high-profile studies publicized in the media, including a recent article on the economic burden of vasomotor symptoms in post-menopausal women cited in The Wall Street Journal blog Pharmalot.
Mr. Lefebvre has also served as a peer reviewer for several journals, including CHEST, Annals of Oncology, Clinical Journal of the American Society of Nephrology, Allergy & Asthma Proceedings, Journal of Managed Care Pharmacy, American Journal of Managed Care, Value in Health, and PharmacoEconomics. He is also a member of the International Society of Pharmacoepidemiology and the International Society of Pharmacoeconomics and Outcomes Research. Prior to joining Analysis Group, Mr. Lefebvre was an economist with the Québec Ministry of Finance.
-
Gastrointestinal manifestations in pediatric and adult patients with Rett syndrome: an analysis of US claims and physician survey data
Journal of Comparative Effectiveness Research, 2024
2024May DM, Neul J, Piña-Garza JE, Kponee-Shovein K, Satija A, Mahendran M, Downes N, Sheng K, Lema N, Boca A, Lefebvre P, Abler V, Youakim JM, Cheng WY
-
Economic Burden of Delayed Diagnosis in Patients with Pulmonary Arterial Hypertension (PAH)
PharmacoEconomics, 2024
2024DuBrock HM, Germack HD, Gauthier-Loiselle M, Linder J, Satija A, Manceur AM, Cloutier M, Lefebvre P, Panjabi S, Frantz RP
-
Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation
Journal of Medical Economics, 2024
2024Kaye DR, Khilfeh I, Muser E, Morrison L, Kinkead F, Urosevic A, Lefebvre P, Pilon D, George DJ
-
Real-World Maintenance Phase Persistence on Ustekinumab and Adalimumab in Ulcerative Colitis
Patient Preference and Adherence, 2024
2024Zhdanava M, Kachroo S, Shah A, Ding Z, Lefebvre P, Zhao R, Kerner C, Pilon D
-
Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer
Journal of medical economics, 2024
2024Bestvina CM, Waters D, Morrison L, Emond B, Lafeuille MH, Hilts A, Lefebvre P, He A, Vanderpoel J
-
Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States
Journal of Medical Economics, 2024
2024Kaye DR, Khilfeh I, Muser E, Morrison L, Kinkead F, Lefebvre P, Pilon D, George D
-
PSA Outcomes and Clinical Surveillance Among Patients With Nonmetastatic Castration-Resistant Prostate Cancer Treated With a Next-Generation Androgen Receptor Inhibitor in Urology Practices With or Without In-Office Dispensing
Journal of Clinical Pathways, 2024
2024Burbage SC, Waters D, Rossi C, Kinkead F, Muser E, Ellis L, Lefebvre P, Pilon D
-
Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States
Journal of Dermatological Treatment, 2024
2024Zhdanava M, Fitzgerald T, Pilon D, Teneralli RE, Shah A, Diaz L, Lefebvre P, Feldman SR
-
Real-world clinical outcomes among patients with metastatic castration-sensitive prostate cancer initiating apalutamide
Future Oncology, 2024
2024Lowentritt BH, Du S, Rossi C, Muser E, Khilfeh I, Kinkead F, Korsiak J, Lefebvre P, Pilon D, Agarwal N
-
Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States
Journal of Managed Care & Specialty Pharmacy, 2024
2024Kaye DR, Khilfeh I, Muser E, Morrison L, Kinkead F, Lefebvre P, Pilon D, George DJ
-
Predictors of High Healthcare Cost Among Patients with Generalized Myasthenia Gravis: A Combined Machine Learning and Regression Approach from a US Payer Perspective
Applied Health Economics and Health Policy, 2024
2024Zhdanava M, Pesa J, Boonmak P, Schwartzbein S, Cai Q, Pilon D, Choudhry Z, Lafeuille MH, Lefebvre P, Souayah N
-
Characterizing the journey of Rett syndrome among females in the United States: a real-world evidence study using the Rett syndrome natural history study database
Journal of Neurodevelopmental Disorders, 2024
2024May D, Kponee-Shovein K, Neul JL, Percy AK, Mahendran M, Downes N, Chen G, Watson T, Pichard DC, Kennedy M, Lefebvre P
-
Comparison of real-world healthcare resource utilization among advanced therapy-naïve and advanced therapy-experienced patients with ulcerative colitis initiated on ustekinumab or vedolizumab
Current Medical Research and Opinion, 2024
2024Zhdanava M, Kachroo S, Boonmak P, Burbage S, Shah A, Korsiak J, Patrick Lefebvre P, Kerner C, Pilon D
-
Treatment patterns for patients with BRCA1/2-positive metastatic castration-resistant prostate cancer
The Oncologist, 2024
2024Bilen MA, Khilfeh I, Rossi C, Morrison L, Diaz L, Hilts A, Lefebvre P, Pilon D, George DJ
-
Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors
Drugs - Real World Outcomes, 2024
2024Walsh JA, Lin I, Zhao R, Shiff NJ, Morrison L, Emond B, Yu LH, Schwartzbein S, Lefebvre P, Pilon D, Chakravarty SD, Mease P
-
Real-World Long-Term Persistence and Surgical Procedure-Free Period Among Bio-naïve Patients with Crohn's Disease and Fistula Initiated on Ustekinumab
Advances in Therapy, 2024
2024Zhdanava M, Kachroo S, Boonmak P, Burbage S, Shah A, Lefebvre P, Kerner C, Pilon D
-
Real-World Treatment Persistence Among Advanced Therapy-Naïve or -Experienced Patients with Ulcerative Colitis Initiated on Ustekinumab or Adalimumab
Advances in Therapy, 2024
2024Zhdanava M, Kachroo S, Boonmak P, Burbage S, Shah A, Korsiak J, Lefebvre P, Kerner C, Pilon D
-
Economic Burden Associated With Nasal Polyposis Recurrence Among Commercially Insured Patients in the United States
Otolaryngology–Head and Neck Surgery, 2023
2023Zhdanava M, Ndife B, Pilon D, Rossi C, Vermette-Laforme M, Lefebvre P, Suh JD
-
Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices
Current Oncology, 2023
2023Sheffield BS, Eaton K, Emond B, Lafeuille MH, Hilts A, Lefebvre P, Morrison L, Stevens AL, Ewara EM, Cheema P
-
Comparison of Clinical Outcomes in Patients with Schizophrenia Following Different Long-Acting Injectable Event-Driven Initiation Strategies
Schizophrenia, 2023
2023Correll C, Benson C, Emond B, Patel C, Lafeuille MH, Lin D, Morrison L, Ghelerter I, Lefebvre P, Mavros P
-
Attainment of Early, Deep Prostate-Specific Antigen Response in Metastatic Castration-Sensitive Prostate Cancer: A Comparison of Patients Initiated on Apalutamide or Enzalutamide
Urologic Oncology, 2023
2023Lowentritt B, Pilon D, Khilfeh I, Rossi C, Muser E, Kinkead F, Waters D, Ellis L, Lefebvre P, Brown G
-
Comparison of Prostate-Specific Antigen Response in Patients with Metastatic Castration-Sensitive Prostate Cancer Initiated on Apalutamide or Abiraterone Acetate: A Retrospective Cohort Study
Urologic Oncology, 2023
2023Lowentritt B, Pilon D, Waters D, Rossi C, Muser E, Kurteva S, Shah A, Khilfeh I, Du S, Ellis L, Lefebvre P, Brown G
-
Ischemic Stroke and Systemic Embolism among One-and-Done Direct Oral Anticoagulant Users with Non-Valvular Atrial Fibrillation
Advances in Therapy, 2023
2023Alberts M, Zhdanava M, Pilon D, Caron-Lapointe G, Lefebvre P, Bookhart B, Kharat A
-
Real-World Racial Variation in Treatment and Outcomes among Patients with Peripheral Artery Disease
Advances in Therapy, 2023
2023Ferdinand KC, Sadik K, Browne R, Desai U, Lefebvre P, Lejeune D, Mahendran M, Laliberté F, Matay L, Armstrong DG
-
Respiratory Syncytial Virus-Related Complications and Healthcare Costs among a Medicare-Insured Population in the United States
Open Forum Infectious Diseases, 2023
2023DeMartino JK, Lafeuille MH, Emond B, Rossi C, Wang J, Liu S, Lefebvre P, Krishnarajah G
-
Venous Thromboembolism Recurrence among One-and-Done Direct Oral Anticoagulant Users: A Retrospective Longitudinal Study
International Journal of Clinical Pharmacy, 2023
2023Alberts M, Zhdanava M, Pilon D, Caron-Lapointe G, Lefebvre P, Bookhart B, Kharat A
-
Epidemiology and Patient Journey of Rett Syndrome in the United States: A Real-World Evidence Study
BMC Neurology, 2023
2023May D, Kponee-Shovein K, Mahendran M, Downes N, Sheng K, Lefebvre P, Cheng WY
-
Projecting the Economic Outcomes of Switching Patients with Schizophrenia from Oral Atypical Antipsychotics to Once-Monthly, Once-Every-3-Months, and Once-Every-6-Months Paliperidone Palmitate
Journal of Managed Care & Specialty Pharmacy, 2023
2023Morrison L, Lin D, Benson C, Ghelerter I, Vermette-Laforme M, Lefebvre P, Pilon D
-
Economic Burden of Illness among Patients with Pulmonary Arterial Hypertension (PAH) Associated with Connective Tissue Disorders (CTD)
Pulmonary Circulation, 2023
2023Tsang Y, Panjabi S, Funtanilla V, Germack HD, Gauthier-Loiselle M, Manceur AM, Liu S, Cloutier M, Lefebvre P
-
Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis
PharmacoEconomics Open, 2023
2023Vanderpoel J, Emond B, Ghelerter I, Milbers K, Lafeuille MH, Lefebvre P, Ellis LA
-
Treatment Persistence among Bio-Naïve Patients with Crohn's Disease Initiated on Ustekinumab or Adalimumab
Current Medical Research and Opinion, 2023
2023Zhdanava M, Ding Z, Manceur AM, Muser E, Lefebvre P, Holiday C, Lafeuille MH, Pilon D
-
Unintended Consequences of Increased Out-of-Pocket Costs During Medicare Coverage Gap on Anticoagulant Discontinuation and Stroke
Advances in Therapy, 2023
2023Salam T, Desai U, Lefebvre P, Jian-Yu E, Greatsinger A, Zacharia N, Laliberté F, Bookhart B, Kharat A
-
Persistence and Dose Escalation During Maintenance Phase and Use of Nonbiologic Medications Among Patients With Ulcerative Colitis Initiated on Ustekinumab in the United States
Crohn's & Colitis 360, 2023
2023Zhdanava M, Zhao R, Manceur AM, Kachroo S, Lefebvre P, Pilon D
-
Ischemic stroke and systemic embolism among patients with non-valvular atrial fibrillation who abandon oral anticoagulant therapy
Current Medical Research and Opinion, 2023
2023Alberts MJ, Zhdanava M, Pilon D, Caron-Lapointe G, Lefebvre P, Bookhart B, Kharat A
-
Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance
Current Medical Research and Opinion, 2023
2023Teeple A, Zhdanava M, Pilon D, Caron-Lapointe G, Lefebvre P, Joshi K
-
Persistence and other treatment patterns among bio-experienced patients with Crohn's disease initiated on ustekinumab or adalimumab
Journal of Managed Care & Specialty Pharmacy, 2023
2023Zhdanava M, Zhao R, Manceur AM, Ding Z, Kachroo S, Holiday C, Lefebvre P, Pilon D
-
Continuity of care among patients newly initiated on second-generation oral or long-acting injectable antipsychotics during a schizophrenia-related inpatient stay
Current Medical Research and Opinion, 2023
2023Patel C, Pilon D, Morrison L, Holiday C, Lafeuille MH, Lefebvre P, Benson C
-
Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib
Future Oncology, 2023
2023Jacobs R, Lu X, Emond B, Morrison L, Kinkead F, Lefebvre P, Lafeuille MH, Khan W, Wu LH, Qureshi ZP, Levy MY
-
Real-world clinical management of individuals with Rett syndrome: a physician survey
Journal of Medical Economics, 2023
2023May DM, Neul JL, Satija A, Cheng WY, Lema N, Boca A, Lefebvre P, Piña-Garza JE
-
Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia
Patient Preference and Adherence, 2023
2023Lu X, Emond B, Morrison L, Kinkead F, Lefebvre P, Lafeuille MH, Khan W, Wu LH, Qureshi ZP, Jacobs R
-
Real-World Incidence of Adverse Clinical Outcomes Among People With Coronary Artery Disease and/or Peripheral Artery Disease in Relation to Vascular Risk in the United States
The American Journal of Cardiology, 2023
2023Desai U, Babcock A, Wang Y, Akbarnejad H, Wirtz EL, Laliberte F, Lefebvre P, Kharat A
-
Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma
Current Medical Research and Opinion, 2023
2023Lu X, Emond B, Qureshi ZP, Wu LH, Forbes SP, Hilts A, Liu S, Lafeuille MH, Lefebvre P, Huang Q, Rogers KA
-
Real-World Treatment Patterns Among Patients with Connective Tissue Disorder-Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis
Advances in Therapy, 2023
2023Sargent T, Tsang Y, Panjabi S, Funtanilla V, Germack HD, Gauthier-Loiselle M, Manceur AM, Cloutier M, Lefebvre P
-
Economic Burden of Commercially Insured Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior in the United States
Journal of Clinical Psychiatry, 2022
2022Pilon D, Neslusan C, Zhdanava M, Sheehan J, Joshi K, Morrison L, Rossi C, Lefebvre P, Greenberg P
-
CLL-492 Real-World Adherence to First-Line Ibrutinib and Acalabrutinib Single-Agent Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Clinical Lymphoma, Myeloma & Leukemia, 2022
2022Lu X, Emond B, Qureshi Z, He J, Qian Y, Huang Q, Lefebvre P, Lafeuille MH, Jacobs R
-
Early prostate-specific antigen response among Black and non-Black patients with advanced prostate cancer treated with apalutamide
Future Oncology, 2022
2022Bivins VM, Durkin M, Khilfeh I, Rossi C, Kinkead F, Waters D, Lefebvre P, Pilon D, Ellis L
-
Characteristics of Real-World Commercially Insured Patients With Treatment-Resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States
Clinical Therapeutics, 2022
2022Karkare S, Zhdanava M, Pilon D, Nash AI, Morrison L, Shah A, Lefebvre P, Joshi K
-
The societal economic value of COVID-19 vaccines in the United States
Journal of Medical Economics, 2022
2022Kirson N, Swallow E, Lu J, Mesa-Frias M, Bookhart B, Maynard J, Shivdasani Y, Lefebvre P
-
Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke
Clinical Lymphoma, Myeloma & Leukemia, 2022
2022Narezkina A, Akhter N, Lu X, Emond B, Panjabi S, Forbes SP, Hilts A, Liu S, Lafeuille MH, Lefebvre P, Huang Q, Choi M
-
Increasing COVID-19 vaccination in the United States: projected impact on cases, hospitalizations, and deaths by age and racial group
Public Health, 2022
2022Kirson N, Swallow E, Lu J, Foroughi C, Bookhart B, DeMartino JK, Maynard J, Shivdasani Y, Eid D, Lefebvre P
-
Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study
Journal of Managed Care & Specialty Pharmacy, 2022
2022Rogers KA, Lu X, Emond B, Côté-Sergent A, Kinkead F, Lafeuille MH, Lefebvre P, Huang Q
-
Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United States
Current Medical Research and Opinion, 2022
2022Liu J, Emond B, Maiese EM, Lafeuille MH, Lefebvre P, Ghelerter I, Wu C, Hurteau JA, Thaker PH
-
Economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the United States: a societal perspective
Journal of Medical Economics, 2022
2022Schein J, Adler LA, Childress A, Cloutier M, Gagnon-Sanschagrin P, Davidson M, Kinkead F, Guerin A, Lefebvre P
-
Understanding the Health System Conditions Affecting the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia in Clinical Practice: A US Healthcare Provider Survey
Neuropsychiatric Disease and Treatment, 2022
2022Zhdanava M, Starr HL, Lefebvre P, Totev TI, Shah A, Sheng K, Pilon D
-
Patient characteristics, treatment patterns, and outcomes among black and white patients with multiple myeloma initiating daratumumab: A real-world chart review study
Clinical Lymphoma, Myeloma & Leukemia, 2022
2022Atrash S, Thompson-Leduc P, Tai MH, Kaila S, Gray K, Ghelerter I, Lafeuille MH, Jayabalan D, Lefebvre P, Rossi A
-
National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States
Journal of Medical Economics, 2022
2022Patel C, Pilon D, Gupta D, Morrison L, Lafeuille MH, Lefebvre P, Benson C
-
Excess healthcare resource utilization and healthcare costs among privately and publicly insured patients with major depressive disorder and acute suicidal ideation or behavior in the United States
Journal of Affective Disorders, 2022
2022Zhdanava M, Voelker J, Pilon D, Joshi K, Morrison L, Sheehan JJ, Vermette-Laforme M, Lefebvre P, Citrome L
-
The Economic Burden of Posttraumatic Stress Disorder in the United States From a Societal Perspective
The Journal of Clinical Psychiatry, 2022
2022Davis LL, Schein J, Cloutier M, Gagnon-Sanschagrin P, Maitland J, Urganus A, Guerin A, Lefebvre P, Houle CR
-
Incidence and economic burden of respiratory syncytial virus among adults in the United States: A retrospective analysis using 2 insurance claims databases
Journal of Managed Care & Specialty Pharmacy, 2022
2022Mesa-Frias M, Rossi C, Emond B, Bookhart B, Anderson D, Drummond S, Wang J, Lefebvre P, Lamerato LE, Lafeuille MH
-
Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer
Journal of Medical Economics, 2022
2022Vanderpoel J, Stevens AL, Emond B, Lafeuille MH, Hilts A, Lefebvre P, Morrison L
-
Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective
Journal of Managed Care & Specialty Pharmacy, 2022
2022Schein J, Adler LA, Childress A, Gagnon-Sanschagrin P, Davidson M, Kinkead F, Cloutier M, Guérin A, Lefebvre P
-
Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab
Current Medical Research and Opinion, 2022
2022Lin I, Melsheimer R, Bhak RH, Lefebvre P, DerSarkissian M, Emond B, Lax A, Nguyen C, Wu M, Young-Xu Y
-
Real-World Prostate-Specific Antigen Response and Treatment Adherence of Apalutamide in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Urology, 2022
2022Lowentritt B, Brown G, Pilon D, Ellis L, Germain G, Rossi C, Lefebvre P, Kernen K, Sieber P, Shore N
-
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma
The Oncologist, 2022
2022Jakubowiak AJ, Kumar S, Medhekar R, Pei H, Lefebvre P, Kaila S, He J, Lafeuille MH, Cortoos A, Londhe A, Mavros P, Lin TS, Usmani SZ
-
Development and evaluation of a predictive algorithm for unsatisfactory response among patients with pulmonary arterial hypertension using health insurance claims data
Current Medical Research and Opinion, 2022
2022Gauthier-Loiselle M, Tsang Y, Lefebvre P, Agron P, Royer J, Lynum KB, Bennett L, Panjabi S
-
Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States
Current Medical Research and Opinion, 2022
2022Emond B, Rossi C, Côté-Sergent A, Bookhart B, Anderson D, Lefebvre P, Lafeuille MH, Donga P
-
Real-World Analysis of Weight Gain and Body Mass Index Increase Among Patients with HIV-1 Using Antiretroviral Regimen Containing Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Neither in the United States
Journal of Health Economics and Outcomes Research, 2022
2022Emond B, Rossi C, Rogers R, Lefebvre P, Lafeuille MH, Donga P
-
Assessing Barriers to Access and Equity for COVID-19 Vaccination in the US
BMC Public Health, 2022
2022Kuehn M, LaMori J, DeMartino JK, Mesa-Frias M, Doran J, Korrapati L, Bhojwani R, Lefebvre P, Kirson N
-
Indicators of Suboptimal Treatment and Associated Healthcare Costs among Patients with Crohn's Disease Initiated on Biologic or Conventional Agents
Crohn's & Colitis 360, 2022
2022Pilon D, Ding Z, Muser E, Manceur AM, Vermette-Laforme M, Lafeuille MH, Lefebvre P
-
Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder
Current Medical Research and Opinion, 2021
2021Zhdanava M, Kuvadia H, Joshi K, Daly E, Pilon D, Rossi C, Morrison L, Lefebvre P, Nelson C
-
Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA
PharmacoEconomics (2021) 39:707–720
2021Zhdanava M, Voelker J, Pilon D, Cornwall T, Morrison L, Vermette‑Laforme M, Lefebvre P, Nash A, Joshi K, Neslusan C
-
The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States
Journal of Clinical Psychiatry, 2021
2021Zhdanava M, Pilon D, Ghelerter I, Chow W, Joshi K, Lefebvre P, Sheehan JJ
-
Special Issue of PharmacoEconomics on Major Depressive Disorders
PharmacoEconomics (2021) 39:617
2021 -
Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclax
Current Medical Research and Opinion, 2021
2021Rogers KA, Emond B, Manceur AM, Kinkead F, Lafeuille MH, Lefebvre P, Huang Q
-
Healthcare resource utilization and costs of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization
Journal of Medical Economics, 2021
2021Desai U, Kharat A, Hess CN, Milentijevic D, Laliberté F, Zuckerman P, Benson J, Lefebvre P, Hiatt WR, Bonaca MP
-
Incidence of Major Atherothrombotic Vascular Events among Patients with Peripheral Artery Disease after Revascularization
Annals of Vascular Surgery, 2021
2021Desai U, Kharat A, Hess CN, Milentijevic D, Laliberté F, Zuckerman P, Benson J, Lefebvre P, Hiatt WR, Bonaca MP
-
Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes
Journal of Hematology, 2021
2021Cheng WY, Satija A, Cheung HC, Hill K, Wert T, Laliberté F, Lefebvre P
-
Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer
Current Medical Research and Opinion, 2021
2021Freedland SJ, Li S, Pilon D, Bhak RH, Narkhede S, Lefebvre P, Young-Xu Y
-
Treatment patterns among adults with attention-deficit/hyperactivity disorder in the United States: a retrospective claims study
Current Medical Research and Opinion, 2021
2021Schein J, Childress A, Adams J, Cloutier M, Gagnon-Sanschagrin P, Maitland J, Bungay R, Guérin A, Lefebvre P
-
Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug-Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression
Advances in Therapy, 2021
2021Zhdanava M, Karkare S, Pilon D, Joshi K, Rossi C, Morrison L, Sheehan J, Lefebvre P, Lopena O, Citrome L
-
Compliance With Cannabis Act Regulations Regarding Online Promotion Among Canadian Commercial Cannabis-Licensed Firms
JAMA Network, 2021
2021Sheikhan NY, Pinto AM, Nowak DA, Abolhassani F, Lefebvre P, Duh MS, Witek Jr TJ
-
Prevalence of post-traumatic stress disorder in the United States: a systematic literature review
Current Medical Research and Opinion, 2021
2021Schein J, Houle C, Urganus A, Cloutier M, Patterson-Lomba C, Wang Y, King S, Levinson W, Guérin A, Lefebvre P, Davis LL
-
Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States
The Journal of Urology, 2021
2021Ryan CJ, Ke X, Lafeuille MH, Romdhani H, Kinkead F, Lefebvre P, Petrilla A, Pulungan Z, Kim S, D'Andrea DM, Francis P, Freedland SJ
-
Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics
Journal of Managed Care & Specialty Pharmacy, 2021
2021Pilon D, Patel C, Lafeuille MH, Zhdanava M, Lin D, Côté-Sergent A, Rossi C, Lefebvre P, Joshi K
-
Prevalence, incidence and economic burden of schizophrenia among Medicaid beneficiaries
Current Medical Research and Opinion, 2021
2021Pilon D, Patel C, Lafeuille MH, Zhdanava M, Lin D, Côté-Sergent A, Rossi C, Joshi K, Lefebvre P
-
Health care resource use, short-term disability days, and costs associated with states of persistence on antidepressant lines of therapy
Journal of Medical Economics, 2021
2021Pilon D, Karkare S, Zhdanava M, Sheehan JJ, Côté-Sergent A, Shah A, Lopena OJ, Lefebvre P, Joshi K, Citrome L
-
Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy
Journal of Comparative Effectiveness Research, 2021
2021Laliberté F, Ashton V, Kharat A, Lejeune D, Moore KT, Jung Y, Lefebvre P, Berger JS
-
Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis
CNS Drugs, 2021
2021Lin D, Thompson-Leduc P, Ghelerter I, Nguyen H, Lafeuille MH, Benson C, Mavros P, Lefebvre P
-
Development and validation of a claims-based model to identify patients at risk of chronic thromboembolic pulmonary hypertension following acute pulmonary embolism
Current Medical Research and Opinion, 2021
2021Kanwar MK, Cole M, Gauthier-Loiselle M, Manceur AM, Tsang Y, Lefebvre P, Panjabi S, Benza RL
-
Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data
Current Medical Research and Opinion, 2021
2021Freedland SJ, Ke X, Lafeuille MH, Romdhani H, Kinkead F, Lefebvre P, Petrilla A, Pulungan Z, Kim S, D'Andrea DM, Francis P, Ryan CJ
-
Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study
Clinical Therapeutics, 2021
2021Ghosh N, Emond B, Lafeuille MH, Côté-Sergent A, Lefebvre P, Huang Q
-
Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US)
Advances in Therapy, 2021
2021Berger JS, Laliberté F, Kharat A, Lejeune D, Moore KT, Jung Y, Lefebvre P, Ashton V
-
Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US population
Journal of Medical Economics, 2021
2021Berger JS, Laliberté F, Kharat A, Lejeune D, Moore KT, Jung Y, Lefebvre P, Ashton V
-
Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population
Current Medical Research and Opinion, 2021
2021Berger JS, Laliberté F, Kharat A, Lejeune D, Moore KT, Jung Y, Lefebvre P, Ashton V
-
Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
BMC Cancer, 2021
2021Atrash S, Thompson-Leduc P, Tai MH, Kaila S, Gray K, Ghelerter I, Lafeuille MH, Lefebvre P, Rossi A
-
Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study
Journal of Health Economics and Outcomes Research, 2021
2021Emond B, Rossi C, Côté-Sergent A, Dunn K, Lefebvre P, Lafeuille MH, Donga P
-
Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions
Journal of Managed Care & Specialty Pharmacy, 2020
2020Zhdanava M, Kuvadia H, Joshi K, Daly E, Pilon D, Rossi C, Morrison L, Lefebvre P, Nelson C
-
Adherence to heart failure management medications following cardiac resynchronization therapy
Current Medical Research and Opinion, 2020
2020Shah BR, DerSarkissian M, Tsintzos SI, Xiao Y, May D, Lu X, Kinrich D, Davis E, Lefebvre P, Duh MS, Dasta JF
-
Use of home health and other healthcare delivery pathways among privately-insured patients with and without treatment-resistant depression
Current Medical Research and Opinion, 2020
2020Pilon D, Szukis H, Singer S, Morrison L, Sheehan JJ, Lefebvre P
-
Costs associated with renal and cardiovascular events among patients with type 2 diabetes mellitus and nephropathy: a cost model based on the CREDENCE clinical trial
Current Medical Research and Opinion, 2020
2020Manceur AM, Durkin M, Kharat A, Bookhart B, Lafeuille MH, Pilon D, Fakih I, Lefebvre P
-
Burden of Crohn's disease in the United States: long-term healthcare and work-loss related costs
Journal of Medical Economics, 2020
2020Manceur AM, Ding Z, Muser E, Obando C, Voelker J, Pilon D, Kinkead F, Lafeuille MH, Lefebvre P
-
Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study
BMC Rheumatology, 2020
2020Hudesman DP, Chakravarty SD, Emond B, Ellis LA, Lefebvre P, Sadik K, Scher JU
-
Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia
Journal of Managed Care & Specialty Pharmacy, 2020
2020El Khoury AC, Pilon D, Morrison L, Shak N, Llaneza A, Kim E, Lefebvre P
-
An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus
Current Medical Research and Opinion, 2020
2020Chow W, Donga P, Côté-Sergent A, Rossi C, Lefebvre P, Lafeuille MH, Emond B, Hardy H
-
US Integrated Delivery Networks Perspective on Economic Burden of Patients with Treatment-Resistant Depression: A Retrospective Matched-Cohort Study
PharmacoEconomics - Open, 2020
2020Pilon D, Szukis H, Joshi K, Singer D, Sheehan JJ, Wu JW, Lefebvre P, Greenberg P
-
Are Medicaid Coverage Gaps Associated with Higher Health Care Resource Utilization and Costs in Patients with Schizophrenia?
Population Health Management, 2020
2020Pilon D, El Khoury AC, Manceur AM, Zhdanava M, Benson C, Lefebvre P, Doshi JA
-
Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
Drugs - Real World Outcomes, 2020
2020Patel C, Emond B, Lafeuille MH, Côté-Sergent A, Lefebvre P, Tandon N, El Khoury AC
-
Healthcare resource utilization and costs associated with venous thromboembolism recurrence in patients with cancer
Journal of Medical Economics, 2020
2020Khorana AA, McCrae KR, Milentijevic D, Laliberté F, Lejeune D, Crivera C, Lefebvre P
-
Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer
Advances in Therapy, 2020
2020Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Lefebvre P, McQuarrie K, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J, Hadaschik BA
-
Prevalence of Potential Drug-Drug Interactions and Pre-existing Conditions for Adverse Events in Augmentation Therapies Among Patients With Treatment-resistant Depression
Psych Congress, 2020
2020Zhdanava M, Karkare S, Pilon D, Joshi K, Rossi C, Morrison L, Sheehan J, Lefebvre P, Lopena O, Citrome L
-
Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer
Urologic Oncology, 2020
2020Freedland SJ, Pilon D, Bhak RH, Lefebvre P, Li S, Young-Xu Y
-
Treatment Patterns and Predictors of Adherence in HIV Patients Receiving Single- or Multiple-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide
Patient Preference and Adherence, 2020
2020Chow W, Donga P, Côté-Sergent A, Rossi C, Lefebvre P, Lafeuille MH, Hardy H, Emond B
-
Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia
Current Medical Research and Opinion, 2020
2020Huang Q, Emond B, Lafeuille MH, Gupta D, Lefebvre P, Sundaram M, Mato A
-
Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels
Cancer Medicine, 2020
2020Khorana AA, Kuderer NM, McCrae K, Milentijevic D, Germain G, Laliberté F, MacKnight SD, Lefebvre P, Lyman GH, Streiff MB
-
Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans
Current Medical Research and Opinion, January 5, 2019
2019Emond B, El Khoury AC, Patel C, Pilon D, Morrison L, Zhdanava M, Lefebvre P, Tandon N, Joshi K
-
The economic burden of psoriasis with high comorbidity among privately insured patients in the United States
Journal of Medical Economics. 2019 Feb;22(2):196-203
2019Pilon D, Teeple A, Zhdanava M, Ladouceur M, Ching Cheung H, Muser E, Lefebvre P
-
Medicaid spending burden among beneficiaries with treatment-resistant depression
Journal of Comparative Effectiveness Research, February 8, 2019
2019Pilon D, Sheehan J, Szukis H, Singer D, Jacques P, Lejeune D, Lefebvre P, Greenberg PE
-
The risk of recurrent VTE and major bleeding in a commercially-insured population of cancer patients treated with anticoagulation
American Journal of Hematology. 2019 Feb;94(2):E58-E61.
2019Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberté F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff MB
-
The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia
Current Medical Research and Opinion. 2019 Mar;35(3):395-405
2019El Khoury AC, Pilon D, Morrison L, Shak N, Vermette-Laforme M, Amos TB, Kim E, Lefebvre P
-
An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records
Journal of Diabetes and its Complications, 2019
2019Wysham CH, Lefebvre P, Pilon D, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Duh MS, Ingham M
-
Development of risk models for major adverse chronic renal outcomes among patients with type 2 diabetes mellitus using insurance claims: a retrospective observational study
Current Medical Research and Opinion, 2019
2019Wysham CH, Gauthier-Loiselle M, Bailey RA, Manceur AM, Lefebvre P, Greenberg M, Duh MS, Young JB
-
Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants
Journal of Medical Economics, 2019
2019Streiff S, Milentijevic D, McCrae KR, Laliberté F, Lejeune D, Lefebvre P, Schein J, Khorana AA
-
Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review
Journal of Medical Economics, 2019
2019Spinowitz B, Pecoits-Filho R, Winkelmayer WC, Pergola PE, Rochette S, Thompson-Leduc P, Lefebvre P, Shafai G, Bozas A, Sanon M, Krasa HB
-
Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants
Journal of Medical Economics, 2019
2019Rozjabek HM, Coleman CI, Ashton V, Laliberté F, Oyefesobi P, Lejeune D, Germain G, Schein JR, Yuan Z, Lefebvre P, Peterson ED
-
Is clinician impression of depression symptom severity associated with incremental economic burden in privately insured US patients with treatment resistant depression?
Journal of Affective Disorders, 2019
2019Pilon D, Sheehan JJ, Szukis H, Morrison L, Zhdanava M, Lefebvre P, Joshi K
-
Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis
PLOS One, 2019
2019Pilon D, Joshi K, Sheehan JJ, Zichlin ML, Zuckerman P, Lefebvre P, Greenberg PE
-
Consideration of Potential Drug-Drug Interactions in Selection of FDA-Approved Drugs Indicated for Prostate Cancer
American Journal of Therapeutics, 2019
2019Pilon D, Ellis LA, Xiao Y, Behl AS, Lefebvre P
-
Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review
PharmacoEconomics - Open, 2019
2019Pergola PE, Pecoits-Filho R, Winkelmayer WC, Spinowitz B, Rochette S, Thompson-Leduc P, Lefebvre P, Shafai G, Bozas A, Sanon M, Krasa HB
-
Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients
Current Medical Research and Opinion, 2019
2019McHorney CA, Peterson ED, Ashton V, Laliberté F, Crivera C, Germain G, Sheikh N, Schein J, Lefebvre P
-
Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma
Clinical Therapeutics, 2019
2019Kavati A, Zhdanava M, Ortiz B, Lecocq J, Schiffman B, Pilon D, Ho H, Lefebvre P, Stone B
-
Long-term omalizumab outcomes in chronic idiopathic urticaria: a real-world study
Allergy & Asthma Proceedings, 2019
2019Kavati A, Zhdanava M, Ortiz B, LeCocq J, Schiffman B, Pilon D, Ching Cheung H, Lefebvre P, Stone BD
-
Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials
Journal of Medical Economics, 2019
2019Kamstra R, Durkin M, Cai J, Bookhart B, Lafeuille MH, Pilon D, Tiggelaar S, Manceur AM, Lefebvre P
-
Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy
Clinical Lymphoma, Myeloma & Leukemia, 2019
2019Emond B, Sundaram M, Romdhani H, Lefebvre P, Wang S, Mato A
-
Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate
PharmacoEconomics - Open, 2019
2019Emond B, Joshi K, El Khoury AC, Lafeuille MH, Pilon D, Tandon N, Romdhani H, Lefebvre P
-
Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors
Current Medical Research and Opinion, 2019
2019Emond B, Ellis LA, Chakravarty SD, Ladouceur M, Lefebvre P
-
Real-world impact of glycated hemoglobin reduction on treatment intensification and glycated hemoglobin goal attainment in type 2 diabetes mellitus patients initiated on a sodium glucose co-transporter 2 (SGLT2) inhibitor (SGLT2i)
Current Medical Research and Opinion, 2019
2019Brunton S, Rozjabek HM, Pilon D, Lafeuille MH, Kamstra R, Wynant W, Bookhart BK, Lefebvre P
-
Long-Term Benefits of Rapid Antiretroviral Therapy Initiation in Reducing Medical and Overall Health Care Costs Among Medicaid-Covered Patients with Human Immunodeficiency Virus
Journal of Managed Care & Specialty Pharmacy, 2019
2019Benson C, Emond B, Romdhani H, Lefebvre P, Côté-Sergent A, Shohoudi A, Tandon N, Chow W, Dunn K
-
Rapid Initiation of Antiretroviral Therapy Following Diagnosis of Human Immunodeficiency Virus Among Patients with Commercial Insurance Coverage
Journal of Managed Care & Specialty Pharmacy, 2019
2019Benson C, Emond B, Lefebvre P, Lafeuille MH, Côté-Sergent A, Tandon N, Chow W, Dunn K
-
Treatment Patterns, Healthcare Resource Utilization, and Spending Among Medicaid-Enrolled Children with Chronic Idiopathic/Spontaneous Urticaria in the United States
Dermatol Ther (Heidelb). Mar 2018;8(1):69-83
2018Williams PV, Kavati A, Pilon D, Xiao Y, Zhdanava M, Balp MM, Lefebvre P, Ortiz B, Hernandez-Trujillo V
-
Implications of stroke and bleeding risk scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation
Current Medical Research and Opinion. 01 Feb 2018;34(2):275-284
2018Kaatz S, Coleman CI, Bookhart B, Laliberté F, Nelson WW, Brown K, Martin S, Schein J, Lefebvre P
-
Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a US Commercial Claims Database
Journal of Clinical Psychiatry. Feb 20 2018;79(2)
2018Amos TB, Tandon N, Lefebvre P, Pilon D, Kamstra RL, Pivneva I, Greenberg PE
-
Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results
Journal of Medical Economics. 2018 Jun;21(6):587-594
2018Wells PS, Lensing AWA, Haskell L, Levitan B, Laliberté F, Durkin M, Ashton V, Xiao Y, Crivera C, Lejeune D, Schein J, Lefebvre P
-
Hba1c control and cost-effectiveness in patients with type 2 diabetes mellitus initiated on canagliflozin or a glucagon-like peptide 1 receptor agonist in a real-world setting
Endocrine Practice. 03 2018;24(3):273-287
2018Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Lefebvre P
-
Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting
Current Medical Research and Opinion. 2018 Jun;34(6):1125-1133
2018Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Lefebvre P
-
Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics
Current Medical Research and Opinion. Feb 28 2018:1-12.
2018Kamstra R, Pilon D, Lefebvre P, Emond B, Joshi K
-
Economic burden of treatment failure in chronic lymphocytic leukemia patients
Current Medical Research and Opinion. 2018 Jun;34(6):1135-1142
2018Wang S, Lafeuille MH, Lefebvre P, Romdhani H, Emond B, Senbetta M
-
Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer
American Journal of Hematology. May 2018;93(5):664-671
2018Streiff MB1, Milentijevic D, McCrae K, Yannicelli D, Fortier J, Nelson WW, Laliberté F, Crivera C, Lefebvre P, Schein J, Khorana AA
-
Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin
Current Medical Research and Opinion. 2018 Jun;34(6):1099-1115
2018Tanton D, Duh MS, Lafeuille MH, Lefebvre P, Pilon D, Zhdanava M, Emond B, Inman D, Bailey RA
-
Asthma control, lung function, symptoms, and corticosteroid sparing after omalizumab initiation in patients with allergic asthma
Allergy and Asthma Proceedings. March-April 2018;39(2):127-135
2018Pilon D, Kavati A, Ortiz B, Paknis B, Vegesna A, Schiffman B, Zhdanava M, Lefebvre P, Stone B
-
Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function
Clinical Nephrology. 01 May 2018;89(5):314-329
2018Weir MR, Haskell L, Berger JS, Ashton V, Laliberté F, Crivera C, Brown K, Lefebvre P, Schein J
-
Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population
CHEST Journal. 2018 Dec; 154(6):1371–1378
2018 -
Risk of Ischemic Stroke in Patients Newly Diagnosed With Heart Failure: Focus on Patients Without Atrial Fibrillation
Journal of Cardiac Failure, March 26, 2018
2018Berger JS, Peterson E, Laliberté F, Germain G, Lejeune D, Schein J, Lefebvre P, Zhao Q, Weir MR
-
Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer
American Journal of Hematology. Feb 2018; 93(3)
2018Streiff M, Milentijevic D, McCrae K, Yannicelli D, Fortier J, Nelson W, Laliberté F, Crivera C, Lefebvre P, Schein J, Khorana A
-
Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data
Cardiovascular Diabetology. Aug 24 2018;17(1):118
2018Young JB, Gauthier-Loiselle M, Bailey RA, Manceur AM, Lefebvre P, Greenberg M, Lafeuille MH, Duh MS, Bookhart B, Wysham CH
-
Health care burden and treatment patterns in commercially insured children with chronic idiopathic/spontaneous urticaria: A real-world study in the United States
Allergy and Asthma Proceedings. 2018 May 19;39(3):201-211
2018Williams P, Kavati A, Pilon D, Xiao Y, Zhdanava M, Balp MM, Lefebvre P, Ortiz B, Hernandez-Trujillo V
-
Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis
Current Medical Research and Opinion. 2018 Sep 5:1-9
2018Pilon D, Amos TB, Kamstra R, Manceur AM, El Khoury AC, Lefebvre P
-
Adherence to rivaroxaban versus apixaban among patients with non-valvular atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users
PLOS One. 2018 Apr 5;13(4):e0194099
2018McHorney CA, Crivera C, Laliberté F, Germain G, Wynant W, Lefebvre P
-
CMS hospital readmission reduction program and anticoagulants received following a total hip and knee arthroplasty discharge
Current Medical Research and Opinion. 2018 Nov;34(11):1967-1974
2018Laliberté F, Coleman CI, Bookhart B, Schein J, Martin S, Wynant W, Xiao Y, Lefebvre P, Kaatz S
-
Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab
Allergy & Rhinology, April 9, 2018
2018Kavati A, Pilon D, Ortiz B, Paknis B, Vegesna A, Schiffman B, Zhdanava M, Lefebvre P, Stone B
-
Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States
Allergy and Asthma Proceedings. 2018 May 7;39(3):191-200
2018Eghrari-Sabet J, Sher E, Kavati A, Pilon D, Zhdanava M, Balp MM, Lefebvre P, Ortiz B, Bernstein JA
-
Risk Factors, Health Care Resource Utilization, and Costs Associated with Nonadherence to Antiretrovirals in Medicaid-Insured Patients with HIV
Journal of Managed Care & Specialty Pharmacy. 2018 Oct;24(10):1040-1051
2018Dunn K, Lafeuille MH, Jiao X, Romdhani H, Emond B, Woodruff K, Pesa J, Tandon N, Lefebvre P
-
Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans
Clinical Therapeutics. 2018 Sep;40(9):1496-1508
2018DerSarkissian M, Lefebvre P, Joshi K, Brown B, Lafeuille MH, Bhak RH, Hellstern M, Bobbili P, Shiner B, El Khoury AC, Young-Xu Y
-
The risk of recurrent VTE and major bleeding in a commercially‐insured population of cancer patients treated with anticoagulation
American Journal of Hematology, November 25, 2018
2018 -
Perspectives on the Common Drug Review Process at the Canadian Agency for Drugs and Technologies in Health
Decision Making in a World of Comparative Effectiveness Research
2017Lefebvre P, Lafeuille M-H, Tiggelaar S
-
Evaluating Non-Pharmaceutical Technologies at the Canadian Agency for Drugs and Technologies in Health
Decision Making in a World of Comparative Effectiveness Research
2017Lefebvre P, Lafeuille M-H, Tiggelaar S
-
Importance of balancing follow-up time and impact of oral-anticoagulant users' selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban
Current Medical Research and Opinion. Jun 2017;33(6):1033-1043
2017Coleman C, Yuan Z, Schein J, Crivera C, Ashton V, Laliberté F, Lefebvre P, Peterson ED
-
Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting
Current Medical Research and Opinion. Oct 2017;33(10):1763-1772
2017Joshi K, Lafeuille MH, Brown B, Wynant W, Emond B, Lefebvre P, Tandon N
-
Out-of-pocket medical costs and third-party healthcare costs for children with Down syndrome
American Journal of Medical Genetics. Part A. Mar 2017;173(3):627-637
2017Kageleiry A, Samuelson D, Duh MS, Lefebvre P, Campbell J, Skotko BG
-
Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE
Clinical Therapeutics. 01 Jul 2017;39(7):1396-1408
2017Khorana AA, Berger JS, Wells PS, Seheult R, Ashton V, Laliberté F, Crivera C, Lejeune D, Schein J, Wildgoose P, Lefebvre P, Kaatz S
-
Public health impact of Rotarix vaccination among commercially insured children in the United States
Vaccine. Sep 05 2017;35(37):5065-5072
2017Krishnarajah G, Kageleiry A, Korves C, Lefebvre P, Duh MS
-
Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse
Clinical Therapeutics. Jul 2017;39(7):1380-1395 e1384
2017Lefebvre P, Muser E, Joshi K, DerSarkissian M, Bhak RH, Duh MS, Shiner B, Young-Xu Y
-
Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk
Current Medical Research and Opinion. Apr 2017;33(4):631-638
2017Nelson WW, Laliberté F, Patel AA, Germain G, Pilon D, McCormick N, Lefebvre P
-
Treatment persistence and hospitalization rates among patients with schizophrenia: a quasi-experiment to evaluate a patient information program
Current Medical Research and Opinion. Apr 2017;33(4):713-721
2017Pilon D, Amos TB, Germain G, Lafeuille MH, Lefebvre P, Benson CJ
-
Duration of treatment in prostate cancer patients treated with abiraterone acetate or enzalutamide
Journal of Managed Care and Specialty Pharmacy. 2017;23(2):225-235
2017Pilon D, Behl AS, Ellis LA, Emond B, Lefebvre P, Dawson NA
-
Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic
Patient Preference and Adherence. 22 Mar 2017;11:619-629
2017Pilon D, Joshi K, Tandon N, Lafeuille MH, Kamstra RL, Emond B, Lefebvre P
-
Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evi
Current Medical Research and Opinion. 03 Oct 2017;33(10):1891-1900
2017Weir MR, Berger JS, Ashton V, Laliberté F, Brown K, Lefebvre P, Schein J
-
Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors
BMC Endocrine Disorders. Jun 08 2017;17(1):32
2017Wysham CH, Lefebvre P, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Chow W, Pfeifer M, Duh MS
-
Relationship between patient copayments in Medicare Part D and vaccination claim status for herpes zoster and tetanus-diphtheria-acellular pertussis
Current Medical Research and Opinion. Jul 2018;34(7):1261-1269
2017Yan S, DerSarkissian M, Bhak RH, Lefebvre P, Duh MS, Krishnarajah G
-
Comparative Effectiveness Research: A Pharmaceutical Industry Perspective on Outlook, Dilemmas, and Controversies
Decision Making in a World of Comparative Effectiveness Research
2017Piech C, Lefebvre P, Pike C
-
Burden of systemic glucocorticoid-related complications in severe asthma(1)
Current Medical Research and Opinion. Jan 2017;33(1):57-65
2017Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Dalal AA
-
A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on longacting mono-
International Journal of COPD. 21 Jun 2017;12:1825-1836
2017Mapel D, Laliberté F, Roberts MH, Sama SR, Sundaresan D, Pilon D, Lefebvre P, Duh MS, Patel J
-
Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics
Journal of Medical Economics. Feb 2018; 21(2):135-143
2017Pilon D, Alcusky M, Xiao Y, Thompson-Leduc P, Lafeuille MH, Lefebvre P, Benson C
-
Assessment of real-world central nervous system events in patients with advanced prostate cancer using abiraterone acetate, bicalutamide, enzalutamide, or chemotherapy
American Health and Drug Benefits. 2017;10(3):143-152
2017Pilon D, Behl AS, Ellis LA, Robitaille MN, Lefebvre P, Dawson NA
-
Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics
Clinical Therapeutics. Oct 2017;39(10):1972-1985 e1972
2017Pilon D, Tandon N, Lafeuille MH, Kamstra R, Emond B, Lefebvre P, Joshi K
-
Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism
Research and Practice in Thrombosis and Haemostasis. 2017 Nov 15;2(1):58-68
2017Berger JS, Seheult R, Laliberté F, Crivera C, Lejeune D, Xiao Y, Schein J, Lefebvre P, Kaatz S
-
Burden of systemic glucocorticoid-related complications in severe asthma
Current Medical Research and Opinion, 2016 Oct 14:1-29
2016Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Dalal AA.
-
Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans with Schizophrenia
The Journal of Clinical Psychiatry, 2016 10; 77(10): e1332-e1341. e-pub ahead of print 2016/08/31; doi: 10.4088/JCP.16m10745
2016Young-Xu Y, Duh MS, Muser E, DerSarkissian M, Faust E, Kageleiry A, Bhak RH, Fu DJ, Lefebvre P, Shiner B
-
Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics
Current Medical Research and Opinion, 2016 04; 32(4): 759-769. e-pub ahead of print 2016/01/12
2016Xiao Y, Muser E, Fu DJ, Lafeuille MH, Pilon D, Emond B, Wu A, Duh MS, Lefebvre P.
-
Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy
Menopause, 2016 06; 23(6): 600-610
2016Simon JA, Laliberte F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P.
-
Retrospective analysis of the impact of increasing access to long acting reversible contraceptives in a commercially insured population
Reproductive Health, 2016 13(1): 96. e-pub ahead of print 2016/08/24
2016Law A, Pilon D, Lynen R, Laliberte F, Gozalo L, Lefebvre P, Duh MS.
-
Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study.
Current Medical Research and Opinion, Opin 2016 06; 32(6): 1151-1159. e-pub ahead of print 2016/04/27
2016Lefebvre P, Pilon D, Robitaille MN, Lafeuille MH, Chow W, Pfeifer M, Duh MS.
-
An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Prac
Clinical Lymphoma Myeloma and Leukemia, 2016 08. e-pub ahead of print 2016/10/01
2016Ma E, Bonthapally V, Chawla A, Lefebvre P, Swords R, Lafeuille MH, Fortier J, Emond B, Duh MS, Dezube BJ.
-
Opportunities for Improving Attainment of Quality Measures in Patients With Type 2 Diabetes Mellitus
American Journal of Managed Care, Volume 20, Number 1, Supplement - January 2014
2014Bailey R, Blonde L, Damaraju CV, Duh MS, Garber L, Gravel J, Grittner A, Lafeuille M, Lefebvre P, Martin S, Meininger G, Rupnow M
-
Incremental direct and indirect costs of untreated vasomotor symptoms
Menopause, August 25, 2014
2014Sarrel P, Portman D, Lefebvre P, Lafeuille M, Grittner A, Fortier J, Gravel J, Duh MS, Aupperle P
-
Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel
Journal of Clinical Pharmacology & Therapeutics, December 2014, Vol. 39, No. 6
2014Olson WH, Ma YW, Laliberte F, Lefebvre P, Crivera C, Schein JR, Fields LE, Dea K, Germain G, Lynch SM
-
Hospital length of stay of nonvalvular atrial fibrillation
Hospital Practice, August 2014, Vol. 42, No. 3
2014Laliberte F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P
-
Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?
Current Medical Research & Opinion, August 2014, Vol. 30, No. 8
2014Laliberte F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P
-
Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants
Current Medical Research & Opinion, August 2014, Vol. 30, No. 8
2014Laliberte F, Coleman CI, Bookhart B, Lefebvre P, Cloutier M, Damaraju CV, Schein JR, Kaatz S
-
Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients
Current Medical Research & Opinion, July 2014, Vol. 30, No. 7
2014Laliberte F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, Lefebvre P
-
Medicaid spending on contraceptive coverage and pregnancy-related care
Reproductive Health, Mar 3, 2014, Volume 11, No. 1
2014Laliberte F, Lefebvre P, Law A, Duh MS, Pocoski J, Lynen R, Darney P
-
Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?
Current Medical Research & Opinion, April 2014, Vol. 30, No. 4
2014Laliberte F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P
-
Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost
Journal of Medical Economics, December 2014, Vol. 17, No. 12
2014Tandon N, Balart LA, Laliberte F, Pilon D, Lefebvre P, Germain G, Prabhakar A
-
Quality measure attainment in patients with type 2 diabetes mellitus
The American Journal of Managed Care, 2014
2014Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P
-
All-cause and disease-related health care costs associated with recurrent venous thromboembolism
Thrombosis and Haemostasis, December 2013, Vol. 110, No. 6
2013Lefebvre P, Laliberte F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein J, Kaatz S
-
Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism
The Patient, September 2013, Vol. 6, No. 3
2013Laliberte F, Bookhart BK, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS
-
Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers
Journal of the Neurological Sciences, July 2013, Vol. 330, No. 1-2
2013Parisé H, Laliberte F, Lefebvre P, Duh MS, Kim E, Agashivala N, Abouzaid S, Weinstock-Guttman B
-
Costs Associated with Intravenous Cancer Therapy Administration in Patients with Metastatic Soft Tissue Sarcoma in a US Population
Sarcoma. 2013;2013:947413
2013Duh MS, Hackshaw MD, Ivanova JI, Kruse G, Miller LA, Lefebvre P, Karner P, Wong B
-
All-Cause and Potentially Disease-Related Health Care Costs Associated with Venous Thromboembolism in Commercial, Medicare, and Medicaid Beneficiaries
Journal of Managed Care Pharmacy (June 2012, Vol. 18, Issue 5)
2012Lefebvre P, Laliberté F, Nutescu E, Duh MS, LaMori J, Bookhart B, Olson W, Dea K, Schein J, Kaatz S
-
Does the Route of Administration for Estrogen Hormone Therapy Impact the Risk of Venous Thromboembolism?
Menopause. 2011 Oct;18(10):1052-9.
2011Laliberte F, Dea K, Duh MS, Kahler K, Rolli M, Lefebvre P
-
Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings
J Med Econ. 2011 Dec 14.
2011Lafeuille M, Bailey R, Vekeman F, Scott McKenzie R, Lefebvre P
-
Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population
J Med Econ. 2011;14(3):324-34.
2011Vekeman F, LaMori J, Laliberte F, Nutescu E, Duh MS, Bookhart B, Schein J, Dea K, Olson W, Lefebvre P
-
Epidemiologic evaluation of cardiovascular risk in patients receiving milnacipran, venlafaxine, or amitriptyline: evidence from French health data
Ann Pharmacother. 2011 Feb 8.
2011Mease PJ, Zimetbaum PJ, Duh MS, Vekeman F, Guerin A, Boerstoel-Streefland M, Jiang W, Lefebvre P
-
Risk of Hepatotoxicity-Related Hospitalizations Among Patients Treated With Opioid-Acetaminophen Combination Prescription Pain Medications
Pain Med. 2010 Nov;11(11):1718-25
2010Duh MS, Vekeman F, Korves C, Lefebvre P, Dial E, Viau-Latremouille D, Stangle B, Lafeuille M, Greenberg P
-
Generic antiepileptic drugs and associated medical resource utilization in the United States
Neurology 2010 74: 1566-1574
2010Labiner D, Paradis P, Manjunath R, Duh MS, Lafeuille M, Latremouille-Viau D, Lefebvre P, Helmers S
-
Comment: the impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa
Ann Pharmacother. 2010;44(3):595; author reply 595-6.
2010Lefebvre P, Vekeman F, Cremieux P
-
Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil
Drugs Aging. 2010; 27(11):903-913.
2010Scharre D, Vekeman F, Lefebvre P, Mody-Patel N, Kahlers K, Duh M
-
Tolerability, Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination with Carboplatin vs Gemcitabine-Carboplatin for the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer: Review
The Oncologist. Oct 2010
2010Holloway R, Grendys E, Lefebvre P, Vekeman F, McMeekin S
-
Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease
The Consultant Pharmacist, 2010
2010Lafeuille MH, Bailey RA, Vekeman F, Kilpatrick BS, Senbetta M, Piech CT, Lefebvre P
-
The impact of drug vintage on patient survival: a patient-level analysis using Quebec’s provincial health plan data
Value in Health 2009; Mar 10 [Epub ahead of print]
2009Lichtenberg F, Grootendorst P, Van Audenrode M, Latremouille-Viau D, Lefebvre P
-
Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries
Curr Med Res Opin. 2009; 25(7):1793-1805
2009Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafeuille M, Lefebvre P, Gaudig M, Duh MS
-
Drug utilization and cost considerations of erythropoiesis-stimulating agents in oncology patients receiving chemotherapy
J Med Econ. 2009; 12(1):1-8
2009Vekeman F, McKenzie R, Bookhart B, Laliberté F, Duh M, Piech C, Lefebvre P
-
Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective
J Manag Care Pharm. 2009; 15(4):312-322
2009Laliberte F, Bookhart B, Vekeman F, Corral M, Duh MS, Bailey R, Piech CT, Lefebvre P
-
Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin
Transfusion. 2009; 49(5):895-902
2009Vekeman F, Bookhart B, White J, McKenzie R, Duh MS, Piech C, Lefebvre P
-
Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis
Clin J Am Soc Nephrol. 2009; 4(4):755-762
2009Parfrey P, Lauve M, Latremouille-Viau D, Lefebvre P
-
An assessment of erythroid response to epoetin alfa as a single agent versus in combination with granulocyte- or granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes using a m
Cancer 2009; 115(4):706-715
2009Mundle S, Lefebvre P, Vekeman F, Duh M, Rastogi R, Moyo V
-
Costs Associated with Intravenous Chemotherapy Administration in Patients with Small Cell Lung Cancer: A Retrospective Claims Database Analysis
Curr Med Res Opin 2008;24(4):967-974
2008Duh M, Reynolds Weiner J, Lefebvre P, Neary M, Skarin AT
-
Clinical Consequences of Generic Substitution of Lamotrigine for Patients with Epilepsy
Neurology 2008 May 27;70(22 Pt 2):2179-86
2008LeLorier J, Duh M, Paradis PE, Lefebvre P, Weiner J, Manjunath R, Sheehy O
-
Economic Impact of Generic Substitution of Lamotrigine: Projected Costs in the United States Using Findings in a Canadian Setting
Current Medical Research and Opinion 2008 Apr;24(4):1069-81
2008LeLorier J, Duh MS, Paradis PE, Latremouille-Viau D, Lefebvre P, Manjunath R, Sheehy O
-
Anaemia and the risk of injurious falls in a community-dwelling elderly population.
Drugs Aging 2008;25(4):325-34.
2008Duh M, Mody SH, Lefebvre P, Woodman RC, Buteau S, Piech CT
-
Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis.
Ann Hematol 2008; 87(7):527-536
2008Moyo V, Lefebvre P, Duh MS, Yektashenas B, Mundle S
-
Management of anaemia: a critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents.
PharmacoEconomics 2008;26(2):99-120.
2008Duh MS, Weiner JR, White LA, Lefebvre P, Greenberg PE
-
Anemia and the risk of injurious falls in a community-dwelling elderly population
Drugs Aging. 2008; 25(4):325-34
2008Duh MS, Mody SH, Lefebvre P, Woodman RC, Buteau S, Piech CT
-
Dose and cost comparison of erythropoietic agents in the inpatient hospital setting
American Journal of Health-System Pharmacy, September 15, 2007;64(18):1943-9
2007McKenzie RS, Mody SH, Piech CT, Watson SH, Duh MS, Lefebvre P, Vekeman F
-
Drug Utilization and Costs of Erythropoietic-Stimulating Agents in Chronic Kidney Disease Patients Not Receiving Dialysis
Managed Care Interface 2007; Dec:14-19
2007Duh MS, Mody SH, Laliberte F, McKenzie RS, Bookhart B, Lefebvre P
-
Is There a Difference in the Cost-Effectiveness of Erythropoietic Therapies for the Treatment of Anemia in Patients Receiving HCV Combination Therapy?
Hepatology. 2007 Jul;46(1):283 [Letter to the Editor]
2007Wu WK, Duh M, Lefebvre P
-
The Economic Impact of Epoetin Alfa Therapy on Delaying Time to Dialysis in Elderly Patients with Chronic Kidney Disease
Disease Management 2007 Feb; 10(1):37-45.
2007Lefebvre P, Duh MS, Mody SH, Bookhart BK, Piech CT
-
Comment on: The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease
Curr Med Res Opin 2007 Jul;23(7):1571-4
2007Einarson T, Machado M, Walker J, Iskedjian M, Cremieux P, Van Audenrode M, Lefebvre P
-
Red blood cell transfusions and the risk of ARDS among critically ill: a cohort study
Crit Care 2007 Jun 6; 11 (3): R63
2007Zilberberg M, Carter C, Lefebvre P, Raut M, Vekeman F, Duh M, Shorr A
-
Benefits Associated with an Early Hemoglobin Response to Epoetin Alfa Therapy in the Treatment of Chemotherapy-Related Anemia
J Natl Compr Canc Netw 2005 Nov;3(6):807-16
2006Campos S, Duh M, Lefebvre P, Rosberg J
-
Dosing Patterns and Costs of Erythropoietic Agents in Patients with Chronic Kidney Disease Not on Dialysis in Managed Care Organizations
Clin Ther 2006 Sep;28(9):1443-50
2006Duh M, Mody S, McKenzie RS, Lefebvre P, Gosselin A, Tak Piech C
-
Relationship Between Hemoglobin Level and Quality of Life in Anemic Patients With Chronic Kidney Disease Receiving Epoetin Alfa
Curr Med Res Opin. 2006; 22(10):1929-1937
2006Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux P
-
Clinical Benefits of Once-Weekly Epoetin Alfa in Anemic Patients With Colorectal Cancer Receiving Chemotherapy
J Support Oncol 2006; 4(5):243-250
2006Chu E, Einhorn L, Lefebvre P
-
Dosing Patterns and Treatment Costs of Erythropoietic Agents in Elderly Patients with Pre-Dialysis Chronic Kidney Disease in Managed Care Organisations
Drugs Aging 2006;23(12):969-76
2006Duh M, Mody S, McKenzie S, Lefebvre P, Gosselin A, Bookhard B, Piech C
-
The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease
Curr Med Res Opin 2006 Dec;22(12):2329-36
2006 -
Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: a Canadian application
J Oncol Pharm Pract. 2006; 12(3):165-178
2006Cremieux P, Vekeman F, Lefebvre P
-
Medical Costs of Untreated Anemia in Elderly Patients with Predialysis Chronic Kidney Disease
J Am Soc Nephrol 2006 Dec;17(12):3497-502
2006Lefebvre P, Duh M, Buteau S, Bookhart B, Mody S
-
Dose-conversion ratio for epoetin alfa and darbepoetin alfa in chemotherapy patients with anemia and cancer
P & T 2006 Oct;31(10):594-603
2006Gosselin A, McKenzie R, Lefebvre P, Mody S, Piech C, Duh M
-
Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations
Curr Med Res Opin. 2006 Jul; 22(9): 1623-31
2006Lefebvre P, Gosselin A, McKenzie RS, Mody SH, Piech CT, Duh MS
-
Assessing the Clinical Benefits of Erythropoietic Agents Using Area Under the Hemoglobin Change Curve
Oncologist. 2005 Jun-Jul;10(6):438-48
2005Duh MS, Lefebvre P, Fastenau J, Piech C, Waltzman R
-
August 5, 2024
-
April 11, 2024
-
February 26, 2024
-
January 29, 2024
-
December 1, 2023
-
October 23, 2023
-
July 25, 2023
-
June 8, 2023
-
March 22, 2023
-
March 3, 2023
-
March 2, 2023
-
December 7, 2022
-
April 12, 2022
-
March 29, 2022
-
October 15, 2021
-
July 12, 2021
-
June 14, 2021
-
June 10, 2021
-
June 8, 2021
-
June 4, 2021
-
April 13, 2021
-
January 21, 2021
